233 related articles for article (PubMed ID: 17440149)
1. Use of epoetin in chronic renal failure.
Coyne DW
JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
[No Abstract] [Full Text] [Related]
2. Epoetin dosing and dialysis facility ownership.
Kliger AS; Nissenson AR
JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
[No Abstract] [Full Text] [Related]
3. Epoetin dosing and dialysis facility ownership.
Regidor DL; Kalantar-Zadeh K; Kovesdy CP
JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
[No Abstract] [Full Text] [Related]
4. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
5. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
6. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
[No Abstract] [Full Text] [Related]
7. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
Eschbach JW
J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
[No Abstract] [Full Text] [Related]
8. Use of Carnitor for Epogen resistant anemia.
Simard JC
ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
[No Abstract] [Full Text] [Related]
10. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Więcek A; Ahmed I; Scigalla P; Koytchev R
Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
[TBL] [Abstract][Full Text] [Related]
11. Effects of Epoetin alfa on hemostasis in chronic renal failure.
Tang WW; Stead RA; Goodkin DA
Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
[TBL] [Abstract][Full Text] [Related]
12. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
Itri LM
Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
[No Abstract] [Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietic agents in peritoneal dialysis.
Muirhead N
Perit Dial Int; 2005; 25(6):547-50. PubMed ID: 16411519
[No Abstract] [Full Text] [Related]
16. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
17. Epoetin bubble: a severe German case Honi soit qui mal y pense.
Wizemann V
Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
[No Abstract] [Full Text] [Related]
18. Relative mortality and epoetin alpha dose among hemodialysis patients.
Coyne DW
Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
[No Abstract] [Full Text] [Related]
19. Relative mortality and epoetin alpha dose in hemodialysis patients.
Cotter DJ; Thamer M; Zhang Y
Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
[No Abstract] [Full Text] [Related]
20. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Jones M; Ibels L; Schenkel B; Zagari M
Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
